TY - JOUR
T1 - Correction
T2 - Van bruggen et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma (Cancers (2020), 12, (3837), 10.3390/cancers12123837)
AU - van Bruggen, Jaco A. C.
AU - Martens, Anne W. J.
AU - Tonino, Sanne H.
AU - Kater, Arnon P.
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - In the original article [1], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”. In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”. The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]: 103. Tinhofer, I.;Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32, 302–309, doi:10.1097/CJI.0b013e318197b5e4. 117. Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Figini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422. 153. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437, doi:10.1172/JCI35017. 192. Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714, doi:10.1182/blood-2012-08-448332. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
AB - In the original article [1], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”. In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”. The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]: 103. Tinhofer, I.;Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32, 302–309, doi:10.1097/CJI.0b013e318197b5e4. 117. Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Figini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422. 153. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437, doi:10.1172/JCI35017. 192. Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714, doi:10.1182/blood-2012-08-448332. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
UR - http://www.scopus.com/inward/record.url?scp=85115379840&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers13194738
DO - https://doi.org/10.3390/cancers13194738
M3 - Comment/Letter to the editor
C2 - 34638518
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 19
M1 - 4738
ER -